Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
Source: View publication →
In patients with severe, NYHA class IV congestive heart failure, the addition of the ACE inhibitor enalapril to conventional therapy significantly reduced mortality and improved symptomatic status compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
CONSENSUS was a monumental breakthrough that fundamentally shifted the paradigm of heart failure treatment from purely symptom-based, hemodynamic relief to targeted neurohormonal modulation. It was the first major trial to demonstrate a profound survival benefit using an ACE inhibitor in severe heart failure, establishing renin-angiotensin-aldosterone system (RAAS) blockade as a non-negotiable cornerstone of guideline-directed medical therapy for heart failure with reduced ejection fraction.
Historical Context
Prior to the 1980s, heart failure was primarily viewed as a strictly hemodynamic failure and was treated with digoxin and diuretics, carrying an exceptionally high mortality rate. While the 1986 V-HeFT I trial was the first to show any mortality benefit (using the vasodilators hydralazine and isosorbide dinitrate), the 1987 CONSENSUS trial revolutionized the field by showing that inhibiting the neurohormonal axis with enalapril dramatically improved survival. This discovery paved the way for the 1991 SOLVD trials, which successfully expanded ACE inhibitor use to patients with milder heart failure and asymptomatic left ventricular dysfunction.
Guided Discussion
High-yield insights from every perspective
Before the CONSENSUS trial, heart failure management primarily focused on improving hemodynamics with diuretics and inotropes. How did the success of enalapril in this trial shift the pathophysiological paradigm of heart failure?
Key Response
It proved that heart failure is fundamentally a neurohormonal disorder. Blocking the renin-angiotensin-aldosterone system (RAAS) prevents maladaptive cardiac remodeling and vasoconstriction, extending survival rather than just temporarily relieving symptoms.
In the CONSENSUS trial, patients on enalapril experienced a higher rate of hypotension and changes in renal function. How do you practically manage the initiation of an ACE inhibitor in a patient with severe NYHA IV heart failure, borderline blood pressure, and baseline renal dysfunction?
Key Response
Initiate at a very low dose, monitor renal function (creatinine and potassium) and blood pressure closely, and consider adjusting concurrent diuretics. A transient bump in creatinine of up to 30 percent is often acceptable and reflects decreased intraglomerular pressure, not necessarily acute tubular injury.
The CONSENSUS trial specifically enrolled patients with severe, NYHA class IV heart failure. How did the subsequent SOLVD trials complement these findings, and what does this progression teach us about the timeline of neurohormonal blockade benefits across the spectrum of heart failure?
Key Response
While CONSENSUS showed survival benefits in severe symptomatic HF, the SOLVD Treatment and Prevention trials demonstrated that enalapril also reduced mortality and delayed HF progression in mild-to-moderate HF and asymptomatic LV dysfunction. This established that RAAS inhibition is beneficial early in the disease process, preventing remodeling before severe symptoms occur.
The CONSENSUS trial was stopped early due to a dramatic mortality reduction, establishing ACE inhibitors as foundational therapy. Decades later, how does the legacy of CONSENSUS complicate the design of modern heart failure trials, such as those evaluating ARNIs or SGLT2 inhibitors?
Key Response
CONSENSUS established an ethical and standard-of-care baseline. Modern trials cannot use a pure placebo for HFrEF; they must test new therapies as add-ons to, or head-to-head against, established guideline-directed medical therapy (GDMT). This requires much larger sample sizes to detect incremental benefits over an already highly effective background regimen.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The CONSENSUS trial was terminated early by the data and safety monitoring committee due to a highly significant reduction in crude mortality. What are the statistical and methodological risks of early trial termination for benefit, and how might this have affected the point estimate of enalapril efficacy?
Key Response
Early termination for benefit risks overestimating the true treatment effect, a phenomenon known as random high or the winner's curse. When a trial stops at a peak of statistical significance, the reported effect size is often exaggerated compared to what would be observed if the trial ran to its planned completion.
As a peer reviewer evaluating the CONSENSUS manuscript in 1987, what concerns might you raise regarding the study blinding and potential for co-intervention bias, given the prominent side effects of enalapril like hypotension?
Key Response
A rigorous reviewer would flag the risk of functional unblinding. Enalapril frequently causes hypotension and mild renal dysfunction, which could easily alert investigators to the treatment assignment. This unblinding might influence how aggressively physicians treat these patients with other background therapies, thereby introducing co-intervention bias.
CONSENSUS was the first trial to demonstrate a mortality benefit for ACE inhibitors in heart failure, laying the groundwork for Class 1 recommendations. How do the 2022 AHA/ACC/HFSA guidelines currently position ACE inhibitors compared to ARNIs for HFrEF, and what historical level of evidence does CONSENSUS provide in this context?
Key Response
CONSENSUS provides foundational Level of Evidence A for RAAS inhibition. However, the 2022 guidelines now recommend ARNIs (sacubitril/valsartan) as the preferred Class 1a agent to reduce morbidity and mortality in HFrEF, relegating ACE inhibitors to a Class 1b recommendation when ARNI administration is not feasible, reflecting the evolution of GDMT beyond the baseline established by CONSENSUS.
Clinical Landscape
Noteworthy Related Trials
SOLVD-Treatment Trial
Tested
Enalapril
Population
Patients with chronic heart failure and reduced ejection fraction
Comparator
Placebo
Endpoint
All-cause mortality
V-HeFT II Trial
Tested
Enalapril
Population
Men with chronic heart failure receiving digoxin and diuretics
Comparator
Hydralazine plus isosorbide dinitrate
Endpoint
All-cause mortality
PARADIGM-HF Trial
Tested
Sacubitril/valsartan
Population
Patients with heart failure and reduced ejection fraction (HFrEF)
Comparator
Enalapril
Endpoint
Composite of cardiovascular death or heart failure hospitalization
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis